Apogee Therapeutics, Inc. financial data

Symbol
APGE on Nasdaq
Location
221 Crescent St., Building 17, Suite 102 B, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.66K % -32.4%
Return On Assets -36.9 % -76.1%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 59.3M shares +4.25%
Entity Public Float 1.43B USD
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 58.8M shares +3.48%
Weighted Average Number of Shares Outstanding, Diluted 58.8M shares +3.48%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 216M USD +58.5%
General and Administrative Expense 66.9M USD +61.1%
Operating Income (Loss) -283M USD -59.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -253M USD -32.5%
Income Tax Expense (Benefit) 234K USD
Net Income (Loss) Attributable to Parent -254M USD -73%
Earnings Per Share, Basic -4 USD/shares -428%
Earnings Per Share, Diluted -4 USD/shares -428%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 108M USD -9.15%
Marketable Securities, Current 419M USD +2.97%
Other Assets, Current 919K USD +132%
Assets, Current 540M USD +1.05%
Property, Plant and Equipment, Net 6.03M USD +326%
Operating Lease, Right-of-Use Asset 9.65M USD -20.5%
Other Assets, Noncurrent 8.74M USD +1601%
Assets 626M USD -19.3%
Accounts Payable, Current 376K USD -83%
Employee-related Liabilities, Current 12.7M USD +83.3%
Accrued Liabilities, Current 29.6M USD +7.5%
Liabilities, Current 34M USD +4.4%
Operating Lease, Liability, Noncurrent 5.77M USD -37.7%
Liabilities 39.8M USD -4.93%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.03M USD -68.6%
Retained Earnings (Accumulated Deficit) -492M USD -106%
Liabilities and Equity 626M USD -19.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -48.5M USD -53.2%
Net Cash Provided by (Used in) Financing Activities 451M USD
Net Cash Provided by (Used in) Investing Activities 13M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 60.1M shares +2.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -34.9M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD -9.37%
Deferred Tax Assets, Valuation Allowance 76.1M USD +152%
Deferred Tax Assets, Gross 78.8M USD +156%
Operating Lease, Liability 11.8M USD +492%
Depreciation 400K USD
Payments to Acquire Property, Plant, and Equipment 4.32M USD +1130%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -256M USD -78.3%
Lessee, Operating Lease, Liability, to be Paid 13.2M USD +496%
Operating Lease, Liability, Current 4.08M USD +42.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.48M USD +260%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.91M USD +214%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.33M USD +664%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.05M USD
Deferred Tax Assets, Operating Loss Carryforwards 16.1M USD +200%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 3.6M USD +299%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.11M USD
Additional Paid in Capital 1.08B USD +11.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 42M USD +134%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares